SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
New Stock Indexes to Track Trends in Healthcare Sector
TEVA
|
|
|
+6.79%
in
31 days
Coming Soon. . . a premium service offered in collaboration with Investars YOU for full access to a global database of over 1,000 stocks which are organized and managed within my 20 ProActive HavRx stock indexes . The expected pricing for premium access is $60 per year and will include full access to all of the component stocks in the indexes and tracking data for the indexes. <> Emerging Cancer Diagnostic / Therapeutic (Dx / Tx) Index The actively managed HavRx Emerging Cancer Dx / Tx Index constituents reflect a cross-section of emerging cancer companies with ><>><>><>><>><>><>><>><>><><>>><><><>>>><>><>><>><><><>>>< />< />><>><>< />< /><><>>>< />< />< />< /><><>>>< />< />><>><>< />< /><><>>>< />< />><>><>><>><>><>><>><>><>><>><>< />< /><><>>>< />< />< />< /><><>>>< />< />><>><>< />< /><><>>>< />< />< />< /><><>>>< />< />< />< /><><>>>< />< />< />< /><><>>>< />< />><>><><><>>>><>><>><>><>><>>...
|
FDA, Clinical Trial Calendar Updates: THRX, GILD, TEVA, ALNY, RNUGF
TEVA
|
|
|
+10.50%
in
205 days
(closed on 10/28/09)
The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 112 entries through 4/6/09. The FDA Calendar includes the following information: company name, ticker, decision date, and description. <> The Clinical Trial Calen>...
|
Momenta Pharma's Three-Part Strategy
TEVA
|
|
|
+1.69%
in
31 days
(closed on 04/06/09)
Momenta Pharma (MNTA) is pursuing a three-part business model which includes complex generic equivalents in partnership with the Sandoz division of Novartis (NVS), proprietary compounds, and follow-on- biologics (FOB). <> Momenta is partnered with Sandoz to develop a generic equivalent (M-Enoxaparin) of the multi-billion dollar injectable blood thinner Lovenox ($3.9B in worldwide sales for 2008). While MNTA + NVS were not the first to file for a generic version of Lovenox, the 180-day exclusivity period awarded to the first-to-file company is set to expire on 4/1/09 for Amphasta>...
|
Big Pharma Goes Generic
TEVA
|
|
|
-1.84%
in
8 days
(closed on 03/06/09)
<> <> <> <> <> <> Sanofi-Aventis (SNY) is now the 11 th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVent>>>>>>...
|
Caraco Pharma Awaits FDA Inspection in May
TEVA
|
|
|
-0.09%
in
20 hours
(closed on 02/26/09)
By Mike Havrilla on 2/25/09 I spoke with the investor relations representative for Caraco Pharma (CPD) earlier this week and received some clarity on the expected timeline for resolving the major overhang on the stock price related to the FDA warning letter over Form 483 concerns by the agency stemming from quality control issues raised during an inspection of manufacturing facilities last year. <> Caraco has responded in full to the warning letter and the FDA will evaluate the corrective actions taken by the Company at its next s>...
|
From the Blogosphere
Sanofi Beats on Higher Revenue – Analyst Blog
|
|
|
Sanofi-Aventis (SNY) recently reported third quarter earnings of $1.25 per American Depository Share (ADS), 4 cents above the Zacks Consensus Estimate of $1.21. The company reported earnings of $1.06 in the year-ago period.
Revenue increased 6% with performance being driven by Lovenox (up 13.7%), Lantus (up 21.7%) and Plavix which continued to grow at a robust rate both in the US (up 11.3%) and Japan (up 50.3%). Emerging markets grew 20.9%. Over-the-counter (OTC) revenue increased 26.3%.
Meanwhile, Eloxatin (down 43%) and Plavix continued to face generic erosion in the US and some parts o...
|
Cephalon Settles Barr Challenge – Analyst Blog
|
|
|
Earlier this month, Cephalon Inc. (CEPH) announced that it has settled its patent infringement case with Barr Pharmaceuticals, which is now owned by Teva Pharmaceutical (TEVA). Barr was looking to market a generic version of Cephalon’s cancer pain management drug, Fentora. As per the terms of the agreement, Barr has been granted a non-exclusive, royalty-free right to sell a generic version of Fentora in October 2018. However, if a generic version of Fentora enters the market prior to that date, Barr will be allowed to launch its generic version provided the other generic company does not...
|
H&Q Healthcare Investors Closed-End Fund Decently Valued
H&Q Healthcare Investors (HQH) appears to a be a decent value now within the closed-end fund universe. It is broadly diversified, and primarily invests in biotechnology, medical devices, pharmaceuticals and medical delivery. It also invests a limited portion of the portfolio in smaller, emerging companies and some restricted securities. In their last SEC filing (as of June 30), the top five holdings were: Teva (TEVA), Gilead (GILD), Celgene (CELG), Amgen (AMGN) and Biogen (BIIB). <>On August 4, the fund discontinued their managed distribution policy. HQH had been paying out 2% of NAV in capit>...
|
Generic Drug Makers
Here’s another terrific post by Pharmboy, this time discussing Generic Drug Makers. - Ilene Generic Drug Makers<script type="text/javascript" src="http://cdn.pis.picapp.com/IamProd/PicAppPIS/JavaScript/PisV4.js"></script> Courtesy of Pharmboy Coming to the end of a good year, and good riddance for some! Whilst the market has been irrational for some time, it is not about what we think but rather about what others that have money think. I have my notions, and here are a few companies that may do well in the New Year with a passed health care reform bill. <>I really like the generic market ri>...
|
Dr. Reddy's Laboratories (DRY) Impressive on Both Fundamental and Technical Basis
|
|
|
While I've traded Dr. Reddy's Laboratories (RDY) in the past, I have not touched it in the past few years; however as we await for the new Market Vectors Indian Small Cap fund to launch I was poking my nose around Indian stocks this weekend since the Indian market has corrected quite a bit (and rebounded from oversold levels last week). So this name came back onto my radar in the limited universe of Indian ADRs. (full list of Indian stocks available at TickerSpy)
Other than Bucyrus (BUCY) I cannot find a better chart, and right now it's all about charts, momentum, and liquidity so let's...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on TEVA |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|